Dr. Reddy's Semaglutide Supply Halted Until October; FY27 Pen Guidance Cut to 6-7M

summarizeSummary

Dr. Reddy's semaglutide scale-up failed validation due to an impurity, halting API supply until at least October. FY27 pen guidance slashed to 6-7 million from ~12 million, with potential inventory write-downs. No safety or regulatory impact, but a major setback for a key growth product.

check_boxKey Events · Product Development and Regulatory · RDY

• Semaglutide Supply Halted

  Scale-up validation of synthetic API failed due to an impurity detected in finished drug product testing. Commercial API supply to partner OneSource is halted until at least October 2026.

• FY27 Pen Guidance Cut to 6-7M

  Management now expects to supply 6-7 million pens between Q3 and Q4 FY27 (November 2026 to March 2027), down from the previously implied ~12 million annual target.

• Potential Inventory Write-Down

  Batches associated with the failed validation may need to be written down; details expected in Q1 FY27 results in two weeks.

• No Safety or Regulatory Impact

  The impurity was found in a scale-up batch never shipped to market. No recall is needed, and existing regulatory filings remain unaffected.

auto_awesomeAnalysis · RDY · Life Sciences

A failed scale-up validation for generic semaglutide API has halted commercial supplies for at least three months. The company expects to resolve the impurity issue by end of September, with market supply resuming in November. FY27 pen guidance is now 6-7 million, down from the previously implied ~12 million, a significant cut for a key growth driver. While no patient safety or regulatory filing impact exists, the delay erodes near-term revenue and may trigger inventory write-downs. The transcript confirms no penalties from partners but acknowledges renegotiation of some down payments. A backup API supplier is a year away, leaving the company dependent on fixing the current process.